A Clinical Pharmacology Study of K-877 Controlled Release Tablet
NCT04079530
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Dyslipidemias
Interventions
DRUG:
K-877 IR 0.2 mg/day
DRUG:
K-877 CR 0.4 mg/day
DRUG:
K-877 CR 0.8 mg/day
Sponsor
Kowa Company, Ltd.